Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biomunex Pharmaceuticals

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

4 comunicati stampa

Guarda tutti i comunicati
14/09/2026
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Biomunex Announces the Upcoming Start of Clinical Development of IPN60330, the First MAIT Engager, a New Therapeutic Class in Oncology, Following the Completion of the FDA Review Period
Fonte
Biomunex Pharmaceuticals
Emittente
Business Wire
1.00
0
26/05/2026
Mercato del lavoro
Industria
Tecnica
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies
Fonte
Biomunex Pharmaceuticals
Emittente
Business Wire
1.00
0
08/01/2026
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Biomunex Pharmaceuticals will showcase its MAIT Engager Platform during the 11th Annual Oncology Innovation Forum in San Francisco
Fonte
Biomunex Pharmaceuticals
Emittente
Business Wire
1.00
0
07/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Fiere
Eventi
Industria
Biomunex to Present Preclinical Data of its MAIT Engager Platform in Immuno-Oncology at 2025 SITC Annual Meeting
Fonte
Biomunex Pharmaceuticals
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0